Page 157 - 南京医科大学自然版

第44卷第12期 崔代迅，杨小慧，冯振卿. 呼吸道合胞病毒疫苗及中和抗体研究进展［J］.
2024年12月 南京医科大学学报（自然科学版），2024，44（12）：1763-1772 ·1771 ·

syncytial virus infection occurring after receipt of live， trial［J］. Lancet Respir Med，2021，9（10）：1111-1120
attenuated，respiratory syncytial virus vaccines［J］. Vac⁃ ［54］A phase Ⅲ double⁃blind study to assess safety and effica⁃
cine，2007，25（42）：7372-7378 cy of an RSV maternal unadjuvanted vaccine，in pregnant
［43］KARRON R A，LUONGO C，THUMAR B，et al. A gene women and infants born to vaccinated mothers［EB/OL］.
deletion that up⁃regulates viral gene expression yields an （2020⁃11⁃20）［2022⁃4⁃12］. https：//clinicaltrials. gov/ct2/
attenuated RSV vaccine with improved antibody responses show/NCT04605159
in children［J］. Sci Transl Med，2015，7（312）：312ra175 ［55］PAPI A，ISON M G，LANGLEY J M，et al. Respiratory
［44］MCFARLAND E J，KARRON R A，MURESAN P，et al. syncytial virus prefusion F protein vaccine in older
Live⁃attenuated respiratory syncytial virus vaccine candi⁃ adults［J］. N Engl J Med，2023，388（7）：595-608
date with deletion of RNA synthesis regulatory protein M2 ［56］GUIÑAZÚ J R，TICA J，ANDREWS C P，et al. 121. A re⁃
⁃ 2 is highly immunogenic in children［J］. J Infect Dis， spiratory syncytial virus prefusion F protein（RSVPreF3）
2018，217（9）：1347-1355 candidate vaccine administered in older adults in a phase
［45］BUCHHOLZ U J，CUNNINGHAM C K，MURESAN P，et Ⅰ/Ⅱ randomized clinical trial is immunogenic［J］. Open
al. Live respiratory syncytial virus（RSV）vaccine candi⁃ Forum Infect Dis，2020，7（Supple 1）：S188-S189
date containing stabilized temperature ⁃ sensitivity muta⁃ ［57］GSK presents positive clinical data on maternal and older
tions is highly attenuated in RSV⁃seronegative infants and adults RSV candidate vaccines［EB/OL］.（2020⁃10⁃21）
children［J］. J Infect Dis，2018，217（9）：1338-1346 ［2022⁃04⁃12］. https：//www. gsk. com/en⁃gb/media/press⁃
［46］MCFARLAND E J，KARRON R A，MURESAN P，et al. releases/gsk⁃presents⁃positive⁃clinical⁃data⁃on⁃maternal⁃
Live ⁃ attenuated respiratory syncytial virus vaccine with and⁃older⁃adults⁃rsv⁃candidate⁃vaccines
M2⁃2 deletion and with small hydrophobic noncoding re⁃ ［58］FELDMAN R G，ANTONELLI⁃INCALZI R，STEENACK⁃
gion is highly immunogenic in children［J］. J Infect Dis， ERS K，et al. Respiratory syncytial virus prefusion F pro⁃
2020，221（12）：2050-2059 tein vaccine is efficacious in older adults with underlying
［47］ROE M K，PEREZ M A，HSIAO H M，et al. An RSV live⁃ medical conditions［J］. Clin Infect Dis，2024，78（1）：
Attenuated vaccine candidate lacking G protein mucin do⁃ 202-209
mains is attenuated，immunogenic，and effective in pre⁃ ［59］A study of a RSV vaccine when given together with TDap
venting RSV in BALB/c mice［J］. J Infect Dis，2022，227 in healthy nonpregnant women aged between 18 to 49
（1）：50-60 years［EB/OL］.（2019⁃08⁃26）［2022⁃04⁃12］. https：//clini⁃
［48］TOPALIDOU X，KALERGIS A M，PAPAZISIS G. Respi⁃ caltrials. gov/ct2/show/NCT04071158
ratory syncytial virus vaccines：a review of the candidates ［60］WALSH E E，PÉREZ MARC G，ZAREBA A M，et al. Ef⁃
and the approved vaccines［J］. Pathogens，2023，12（10）： ficacy and safety of a bivalent RSV prefusion F vaccine in
1259 older adults［J］. N Engl J Med，2023，388（16）：1465-1477
［49］KARRON R A，LUONGO C，MATEO J S，et al. Safety ［61］Safety and efficacy of ARS13 in the elderly［EB/OL］.
and immunogenicity of the respiratory syncytial virus vac⁃ （2020⁃12⁃23）［2022⁃04⁃12］. https：//clinicaltrials. gov/
cine RSV/ΔNS2/Δ1313/I1314L in RSV⁃seronegative chil⁃ ct2/show/NCT04681833
dren［J］. J Infect Dis，2020，222（1）：82-91 ［62］TORREY H L，KALIAPERUMAL V，BRAMHECHA Y，
［50］MALKIN E，YOGEV R，ABUGHALI N，et al. Safety and et al. Evaluation of the protective potential of antibody
immunogenicity of a live attenuated RSV vaccine in healthy and T cell responses elicited by a novel preventative vac⁃
RSV ⁃ seronegative children 5 to 24 months of age［J］. cine towards respiratory syncytial virus small hydrophobic
PLoS One，2013，8（10）：e77104 protein［J］. Hum Vaccin Immunother，2020，16（9）：
［51］CHIRKOVA T，HA B，RIMAWI B H，et al. In vitro model 2007-2017
for the assessment of human immune responses to subunit ［63］Study of VN⁃0200 in apanese healthy adults and elderly
RSV vaccines［J］. PLoS One，2020，15（3）：e0229660 subjects［EB/OL］.（2021⁃06⁃04）［2022⁃04⁃12］. https：//
［52］CRANK M C，RUCKWARDT T J，CHEN M，et al. A proof clinicaltrials. gov/ct2/show/NCT04914520
of concept for structure ⁃ based vaccine design targeting ［64］FALSEY A R，WILLIAMS K，GYMNOPOULOU E，et al.
RSV in humans［J］. Science，2019，365（6452）：505-509 Efficacy and safety of an Ad26. RSV. preF⁃RSV preF pro⁃
［53］RUCKWARDT T J，MORABITO K M，PHUNG E，et al. tein vaccine in older adults［J］. N Engl J Med，2023，388
Safety，tolerability，and immunogenicity of the respiratory （7）：609-620
syncytial virus prefusion F subunit vaccine DS ⁃ Cav1：a ［65］GROOTHUIS J R，SIMOES E A，LEVIN M J，et al. Pro⁃
phase 1，randomised，open⁃label，dose⁃escalation clinical phylactic administration of respiratory syncytial virus im⁃